Condition: Acute Lymphoblastic Leukemia · Sponsor: Northside Hospital, Inc.
Changing the schedule of intrathecal chemotherapy to be given before and during blinatumomab will maintain the anti-leukemic effects of this drug while at the same time adding the benefit of limiting the neurotoxicity associated with cytokine release.
This description comes directly from the study's public registry record.
Caitlin Guzowski · 404-851-8523 · caitlin.guzowski@northside.com
Always discuss trial participation with your own doctor first.
| Northside Hospital | Atlanta, Georgia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05519579